Earlier quoted context omitted.
If anyone's interested, England's system of health technology assessment (HTA) for the NHS is extremely transparent and world-leading. It's one of the things that we Brits should be extremely proud of (although pharma-sponsored sob story campaigns in tabloid newspapers may suggest otherwise). All new technologies are investigated in terms of incremental quality of life gain (vs current treatment norms) and changes in…
> It's one of the things that we Brits should be extremely proud of (although pharma-sponsored sob story campaigns in tabloid newspapers may suggest otherwise). They consider everything in a wider context of opportunity cost of adopting a new treatment and budget constraints. For context, this is literally what risk-bearing entities in the US already do (both insurers and at-risk providers). I could get behind the st…
When NICE decides not to fund something they have clear evidence that it is worse than current treatment, not just that it is more expensive than current treatment.
See, for example, Abraxane, a chemotherapy for pancreatic cancer.
To be accepted all it has to do is either:
i) Be better than current first line treatment or
ii) Have less side effects, and thus be usable as a second line treatment or
iii) Be much cheaper
It's fantastically expensive, has many side effects, and is less effective than current treatment. So it fails all three. But you wouldn't be able to tell that from the pharma-sponsored advocacy groups. Those groups talk about "2 years of life", when the manufacturer's own data talks of just 3 weeks.
It's incorrect to say that NICE has a profit motive. They very clearly - and this is the point of transparency - don't.